文献速递银屑病与炎症性皮肤病

阿达木单抗与富马酸酯对银屑病患者心血管危险因素的不同影响:前瞻性随机观察者盲法头对头试验

Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-02

阿达木单抗组FMD显著升高且hsCRP较富马酸酯组显著下降,富马酸酯则降低总胆固醇与载脂蛋白B;两药对心血管系统的作用途径不同。

要点

  • 阿达木单抗改善血管内皮功能(FMD)并降低hsCRP等炎症指标。
  • 富马酸酯对胆固醇代谢更有利,可降低总胆固醇与载脂蛋白B。
  • 两药对银屑病严重程度(PASI)的改善差异无统计学意义。

核心结论

  • 阿达木单抗与富马酸酯均对心血管系统产生影响,但作用途径不同:前者抗炎并改善FMD,后者与胆固醇代谢产生有利交互。

研究设计与样本

  • 在基线(v0)和6个月(v6)评估血流介导舒张(FMD)、硝酸甘油介导舒张(NMD)、颈动脉内中膜厚度(CIMT)及血压。
  • 在基线(v0)、3个月(v3)和6个月(v6)分析皮肤疾病严重度、炎症及脂质心血管危险标志物。

主要发现

  • 阿达木单抗组FMD从v0的5.9%(SD 6.4%)升至v6的8.0%(SD 4.8%),P=0.048;富马酸酯组从7.0%(SD 4.1%)至8.4%(SD 6.1%),P=0.753。
  • 与富马酸酯组相比,阿达木单抗组hsCRP显著下降(v0: 0.39 mg/dL(SD 0.38),v6: 0.39 mg/dL(SD 0.48),P=0.043)。
  • 富马酸酯较阿达木单抗降低总胆固醇(P=0.046)和载脂蛋白B(P=0.041)水平。
  • 阿达木单抗组PASI平均下降幅度大于富马酸酯组[-71.1%(SD 29.9)vs. -54.6%(SD 45.7%)],但差异无统计学意义(P=0.116)。
  • 其他血流动力学参数未见显著变化。

关键数值与推荐

  • FMD在阿达木单抗组显著升高(P=0.048),富马酸酯组无显著变化(P=0.753)。
  • hsCRP在阿达木单抗组较富马酸酯组显著下降(P=0.043)。
  • 富马酸酯较阿达木单抗降低总胆固醇(P=0.046)与载脂蛋白B(P=0.041)。
  • PASI下降幅度两组差异无统计学意义(P=0.116)。

临床怎么用

  • 对合并心血管风险的银屑病患者,选择生物制剂或传统系统治疗时可考虑药物对心血管标志物的不同影响。
  • 阿达木单抗可能更适合需同时控制炎症与内皮功能的患者,富马酸酯可能对脂质代谢更有利。
  • 治疗选择应个体化,结合患者心血管风险谱综合评估。

局限性

  • 部分指标标准差较大,组间比较的统计效能有限。
  • 未报告长期心血管结局事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of adalimumab and fumaric acid esters (FAE) on the cardiovascular risk associated with psoriasis has only been investigated scarcely in randomized controlled studies. OBJECTIVE: The aim of this prospective, randomized controlled head-to-head trial was to compare the influence of adalimumab and FAE on cardiovascular disease markers in psoriasis patients. METHODS: Sixty-five patients with moderate to severe plaque psoriasis were randomly assigned to adalimumab or FAE treatment for 6 months. Cardiovascular haemodynamic parameters [flow-mediated dilation (FMD), nitro-glycerine mediated dilation (NMD) and carotid intima-media thickness (CIMT), blood pressure] were assessed at baseline (v0) and after 6 months (v6). Cutaneous disease severity, inflammatory and lipid cardiovascular risk markers were analysed at baseline(v0), after 3 (v3) and 6 months (v6). RESULTS: After 6 months of treatment FMD in the adalimumab group increased significantly [v0 5.9% (6.4% SD), v6 8.0% (4.8% SD), P = 0.048) but not in the FAE group. (v0 7.0% (4.1% SD), v6 8.4% (6.1% SD), P = 0.753]. This was paralleled by a significant decrease of high sensitive C-reactive protein (hsCRP) in the adalimumab group in comparison to the FAE group (v0: 0.39 mg/dL (0.38 SD), v6: 0.39 mg/dL (0.48 SD), P = 0.043). No significant changes were observed in any other haemodynamic parameters. FAE, however, additionally decreased total cholesterol (P = 0.046) and apolipoprotein B (P = 0.041) levels compared to adalimumab. Mean Psoriasis Area and Severity Index (psoriasis area severity score) reduction was greater but not significant (P = 0.116) under adalimumab treatment compared to FAE treatment [-71.1% (29.9 SD) vs. -54.6% (45.7%)]. CONCLUSION: In our study, both treatments were documented to exert effects on the cardiovascular system. While adalimumab showed anti-inflammatory effects and improved FMD, FAE interacted favourably with the cholesterol metabolism.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Holzer G, Hoke M, Sabeti-Sandor S, et al. Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial. J Eur Acad Dermatol Venereol. 2020. PMID: 32426884. doi:10.1111/jdv.16635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。